New oral anticoagulants: comparative pharmacology with vitamin K antagonists. - Wikidata - awgldk - TriplyDB

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

http://www.wikidata.org/entity/Q38071973

about

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes.Evolving use of new oral anticoagulants for treatment of venous thromboembolism Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.Expanding use of new oral anticoagulants Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease.My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation.Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis Left Atrial Appendage Thrombus Resolution with Reduced Dose Apixaban.New oral anticoagulants and the cancer patient.Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension.Management of venous thromboembolism--controversies and the future.Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.Dabigatran etexilate for venous thromboembolism: a safety evaluation.The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.Direct oral anticoagulants: integration into clinical practice.Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage.Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.Balancing ischaemia and bleeding risks with novel oral anticoagulants.Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.New oral anticoagulants - a guide for ENT surgeons.The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.Novel anticoagulants - an update on the latest developments and management for clinicians treating patients on these drugs.Percutaneous gastrostomy: troubleshooting complications.Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review.Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.Apixaban-induced liver injury.Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report Portal vein thrombosis in cirrhosis: Controversies and latest developments.Initiation of glucose-lowering treatment decreases international normalized ratio levels among users of vitamin K antagonists: a self-controlled register study.Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study).Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.

P2860

Q26782483-5F6CD5DF-EB79-4BF9-A275-48E66345FB3E Q28078747-B315D5BC-1E53-4D55-B358-1D0D6003AAEF Q33891915-0B6AC2B4-6410-4DA3-9638-57CD1AA1752C Q34047801-63F7D3D1-4B23-4169-8A2A-EEE003D4B132 Q34047821-504369D6-6CAC-4DF6-9FBB-F1904C20C9A5 Q34206252-64997331-C890-4224-A7CB-0FB4F9948DC2 Q34312531-8F6E0819-2190-4889-A5ED-51041E6488E0 Q34482427-52B8FB97-F14B-42EC-91B3-D863A3529250 Q34570893-913886FC-5BB0-453E-A4AE-90C96694D2C8 Q36396649-2CAAAE6E-F504-4497-8FF9-EEA91A0CCA9E Q36933789-FB9D8F48-041B-45A3-8EF2-87F46337BD58 Q37115545-D7ABEA70-39A7-4FF9-AEC7-0E513C21B13D Q37218993-C30FE3B6-D0AF-4768-939A-0FDAAD23AF31 Q37468780-39385B13-2A46-4DC3-B3CB-8FBFECAEE5D2 Q37519054-BCA34E78-739E-48FA-9BD1-29C96047E715 Q37582128-EC40D609-2260-4840-8CB8-F88D58BC9B11 Q38093286-530EBE94-3103-49C7-B88D-E1093212AC08 Q38186641-5CFAB157-8B68-4EE6-977C-EEB53A7767E8 Q38193599-29962311-1E26-478C-93CE-751D832910D1 Q38198557-36275B91-EB48-4E9C-BC72-C9183B23C1DA Q38228212-EFF27152-462B-4C8C-86BB-B52E059AA4E2 Q38236837-36B0157C-97B4-4179-965A-8D9CA7E776DF Q38262325-EFF51A54-196D-4B3B-ADB0-185D4F35E8B8 Q38264835-089847D9-48D7-4B77-8F99-8FD45C8FA9A6 Q38345740-DE6692F6-44AF-47DB-86B5-4CFF967E48E7 Q38655829-D4AE6CC7-6D99-4ADE-B3FF-DFC659A7F065 Q38718202-BA37C5B8-FA1D-48C5-9F70-730F02EE0382 Q38792322-07E77B86-077A-4081-9839-7B9806A57DCA Q38793747-7E0F285A-ACD0-43C0-B30C-B59EBA26DD17 Q38857379-8A824951-ABA8-45D4-9B37-B805424277EA Q38958252-176A674A-3F08-40B4-98F8-0FD16EA1DE8D Q39032909-071614EA-ECCC-440B-A77C-9BA3D8E7E74F Q39233249-157B73AD-66D7-4C04-AE62-BAFE7ABE8A5D Q40533024-DB0AA288-E1C8-4111-BEE8-0F2B523EF187 Q42289797-D4785602-B7C5-45B5-928C-C2B7583D7AE2 Q42533695-8C3E0BFC-02CD-40D5-8289-3EBCA39398D6 Q48106202-32245257-CA54-45A5-B44D-5589C29683B2 Q48152726-3A1132B6-9AA1-43FF-B1BE-289ECC9FACCA Q50002162-C7CB9377-3F80-4A7E-8250-F56CCF039252 Q50193651-F24B88E6-55A5-49AB-9504-4E87470CF66C

P2860

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

http://www.wikidata.org/entity/Q38071973

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

@en

type

label

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

@en

prefLabel

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

@en

P1433

Q38071973-40FEB64A-8BCF-4B43-AA9A-508E5B8DAAEB

P1476

Q38071973-E78AAACA-5769-49D1-ABB3-1053DE4FEBAF

P2093

Q38071973-27B95329-D64B-4EBB-9F55-C6D924BC28C4

P2860

Q38071973-0069B487-6A52-4D2E-B5EC-6E93464F424D

Q38071973-014E48E4-EAC9-44E8-AC31-F6421C000EFD

Q38071973-04065E2D-EA4A-4A38-9720-0D1AE128B5AF

Q38071973-09EC261B-07D0-4601-8DC0-B7C20ABF39AD

Q38071973-15ACA06C-4D33-4F37-AB14-91E8CD1162A2

Q38071973-1D679B02-8591-4410-BC1B-E75309DA263E

Q38071973-1F06AC97-F2B1-47D5-A31B-7F0FB4337381

Q38071973-1FC232B3-F668-40C1-BAC8-B44467141C2E

Q38071973-1FE3C894-5186-4AD4-BB44-9930BBC1FFBE

Q38071973-2044A6D4-2C1C-4982-9C45-6F7EA3879E8D

P2888

Q38071973-983EA2C8-79D4-42C6-9F9A-94F13E63489B

P304

Q38071973-C42E7BBD-CD5C-4B0E-8BEE-D2522773189D

P31

Q38071973-3D89909A-CBF6-4EC2-B1AC-33863320EA35

P356

Q38071973-C03D00EC-5B24-4ED2-AADC-E2BA947AFB66

P433

Q38071973-299A89B2-FD79-4017-8C85-E5922AF5F686

P478

Q38071973-EFDF7BB9-2FDE-46D4-A4E8-2EAB58DB9DB6

P577

Q38071973-8C60CF82-1226-4AE6-8787-817AC75E1484

P6179

Q38071973-96EA9B7D-585D-4D86-B7E7-4B9C4735986B

P698

Q38071973-432BA79F-5244-4CDE-B2AE-BC78BC42C50A

P921

Q38071973-46c18e44-c225-4979-a1d2-8666413f7906

Q38071973-47AFC86A-700C-4B94-8205-1885110F4486

Q38071973-57D62A08-4866-4964-8369-38DB02C6E0D9

Q38071973-6CCDE354-F3C3-4B1B-8715-5D42883122DF

P356

S40262-012-0030-9

P1433

Clinical Pharmacokinetics

P1476

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

@en

P2093

Francesco Scaglione

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-based design of novel potent nonpeptide thrombin inhibitors

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

Guidelines on oral anticoagulation with warfarin - fourth edition

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Dabigatran versus warfarin in patients with atrial fibrillation

New anticoagulants for treatment of venous thromboembolism

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

P2888

s40262-012-0030-9

P304

69-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-012-0030-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1006853020

http://www.w3.org/2001/XMLSchema#string

P698

23292752

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation